Showing results (41-50 of 46) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Pulmonary Circulation|December 21, 2017
Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosisLewis Renshall, Nadine Arnold, Laura West, et al.Pulmonary Circulation|November 26, 2020
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive ratsArgen Mamazhakypov, Astrid Weiß, Sven Zukunft, et al.Journal of Cardiovascular Pharmacology|August 1, 2015
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary HypertensionMarc Iglarz, Kyle Landskroner, Yasmina Bauer, et al.Chemmedchem|March 12, 2025
Discovery of Galactopyranose-1-carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin-3 InhibitorsCornelia Zumbrunn, Luboš Remen, Christoph P Sager, et al.The European Respiratory Journal|June 27, 2015
Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosisDjuro Kosanovic, Himal Luitel, Bhola Kumar Dahal, et al.The Journal of Pharmacology and Experimental Therapeutics|March 12, 2025
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosisMagdalena Birker-Robaczewska, Maxime Boucher, Giulia Ranieri, et al.Pageof 5